Recently, the Indian Prime Minister urged the responsible use of antibiotics, warning of their declining effectiveness against infections like pneumonia and urinary tract infections.
- His remarks highlight growing concern over antimicrobial resistance (AMR), which causes around 1.27 million deaths annually (WHO data).
Concerns & Challenges due to AMR
- Economic and Health Burden:
- Rising healthcare costs: AMR has already increased global healthcare expenditure by $66 billion.
- Potential escalation: If resistance rises unchecked, AMR-related costs could reach $325 billion, and the global economy could shrink by $1.7 trillion by 2050.
- Treatment gaps: Lack of access to high-quality treatment and insufficient investment in new antibiotics exacerbate the problem.
- Public Awareness Deficit:
- Misuse and overuse of antibiotics persist due to limited awareness among patients and consumers.
- Insufficient focus on correct dosing, frequency, and duration among healthcare professionals.
- Institutional and Infrastructure Gaps:
- Fragmented coordination among central, state, and industry stakeholders.
- Limited availability of essential diagnostic tests and laboratory support at district and sub-district levels.
- Weak monitoring and auditing mechanisms to ensure compliance with AMR guidelines.
About Antibiotics & Penicillin
- Antibiotics: Substances that kill or inhibit microorganisms; classified as natural, semi-synthetic, or synthetic.
- Legacy & Challenge: Enabled mass production of antibiotics (WWII), foundation for modern medicine; today, antimicrobial resistance (AMR) is a growing concern.
- Discovery: Penicillin, the first widely used antibiotic, was discovered by Alexander Fleming in 1928 from the mold Penicillium notatum.
- Action: Penicillin kills bacteria by inhibiting cell wall synthesis, without harming human cells.
- Significance: It revolutionised medicine by curing bacterial infections like pneumonia, scarlet fever, and syphilis, drastically reducing mortality rates.
|
Way Forward
- Economic and Strategic Measures:
- Invest in high-quality treatment and antibiotic innovation, potentially reducing costs by $97 billion by 2050.
- Foster global coordination through coalitions for pooled research funding and collective procurement of innovative antibiotics.
- Public Awareness and Medical Training:
- Launch national campaigns akin to HIV, polio, and TB programs to educate the public on AMR risks.
- Implement ICMR-mandated training programs for healthcare professionals emphasizing rational antibiotic use.
- Institutional and Infrastructure Strengthening:
- Establish a coordinated platform integrating central/state agencies and industry for structured AMR policy implementation.
- Ensure district-level diagnostic capacity for timely detection.
- Institutionalize monitoring and auditing to enforce compliance with AMR protocols.
Conclusion
The Prime Minister’s call should drive a One Health approach, integrating human, animal, and environmental health through public awareness, medical training, infrastructure strengthening, and global cooperation to effectively combat antimicrobial resistance.